Hyponatremia Clinical Trial
Official title:
Impact of Hyponatremia on Muscle Strength, Gait and Balance, and Cognitive Function: a Prospective Observational Study
In this study patients with hyponatremia, defined as a serum sodium < 126 mmol/L on admission to the hospital will be tested for muscular power by use of a hand grip dynamometer, for cognitive function by use of the Montreal-Cognitive-Assessment and gait stability by use of the Tinetti test. The tests will be performed on admission as well es after correction of hyponatremia.
The investigators broad objective is to examine in a prospective study whether an association
exists between hyponatremia and psychomotor deficits. The specific aims are:
A.) To measure muscle strength by use of a dynamometer in patients presenting with moderate
to severe hyponatremia (serum sodium ≤ 125 mmol/L) at the emergency department before and
after correction of hyponatremia (serum sodium ≥ 135 mmol/L).
B.) To test for balance and gait disorders before and after correction of hyponatremia C.) To
investigate whether presence of hyponatremia is associated with cognitive impairment that
isreversible after correction of serum sodium.
The hypothesis is that hyponatremia is associated with reduced muscle strength, impaired
balance, and cognitive impairment, and that the correction of the serum sodium will lead to
an improvement of these parameters.
Design & Setting
The investigators will conduct a single-center, prospective, observational study at the
General Hospital Solothurn. The study will be conducted at the Department of Emergency
Medicine, where patients will be screened for hyponatremia, and the Department of General
Internal Medicine, where screening will occur both in the inpatient and outpatient services.
If a serum sodium of 125 mmol/L is detected in a blood sample sent from the Department of
Emergency Medicine or General Internal Medicine, the Center for Laboratory Medicine will
notify the study team responsible for patient enrollment using a dedicated pager. Then, a
member of the study team will approach potential participants, inform them about the study
goals and procedures, obtain informed consent, and enroll them into the study. Patients
enrolled in the Department of Emergency Medicine needing hospitalization will primarily
hospitalized in the Department of General Internal Medicine, unless hospitalization at
specialist ward is indicated.
Patient enrollment criteria
Inclusion criteria Consecutive patients aged 18 years or above presenting with moderately to
severe hyponatremia (serum sodium ≤ 125 mmol/L after correction for blood glucose), who give
informed consent.
Exclusion criteria
- Patients who do not give or are not able to give informed consent.
- Patients with concomitant Potassium dysregulation (K+<3.5 mmol/l or K+>5.0 mmol/l)
Baseline data collection
1. Clinical data Of all patients included in the study, data on age, sex, comorbidities,
and current medications taken by the patients will be gathered.
2. Serum sodium measurements Measurements of serum sodium will be performed through the
Center for Laboratory Medicine of the General Hospital Solothurn. Sodium determination
will be performed by use of ion-selective electrode using the ICT (Na+, K+, Cl-) Sample
Diluent Kit, Abbott Laboratories, Chicago, IL, USA. Additionally, serum osmolality,
potassium, magnesium, calcium, creatinine, albumin and hemoglobin will be measured. All
of these parameters are standard measurements in case of a severe electrolyte disorder
and are part of clinical practice in the care for patients with electrolyte disorders.
All laboratory parameters will be measured at baseline and after correction of serum
sodium. In order to avoid multiple blood drawings for the patient the parameters
mentioned above will be reordered from blood already taken for serum sodium
determination.
Endpoints A.) Muscle strength in pounds and kilogram before and after correction of
hyponatremia.
B.) Results for the Tinetti performance-oriented mobility assessment (POMA) to evaluate
static and dynamic balance abilities during and after correction of hyponatremia.
C.) Results for the Montreal Cognitive Assessment (MOCA) test to assess mild cognitive
impairment before and after correction of hyponatremia.
Muscle strength at handgrip will be measured at time of presentation at the clinic with a
serum sodium ≤ 125 mmol/L and 24 to 48 hours after correction of hyponatremia at a serum
sodium ≥ 135 mmol/L using the Jamar ® hydraulic hand dynamometer, Lafayette Instrument,
Lafayette, IN, USA. Strength will be measured in pounds and kilograms thrice at baseline and
after correction of hyponatremia, respectively. The best result of each test will be used for
the analysis. The test will be conducted by either Drs. Woitok or Lindner.
The Tinetti POMA, a simple, easily administered test, will be used to measure patients' gait
and balance taking about 10 to 15 minutes. Scoring of the Tinetti Assessment Tool is done on
a three point ordinal scale with a range of 0 to 2. A score of 0 represents the most severe
impairment, while a 2 would represent patient independence. The individual scores are then
combined to form three measures; an overall gait assessment score, an overall balance
assessment score, and a gait and balance score. The test has been validated in several
studies and found to be a useful screening tool for gait instabilities and prediction of
falls. The Tinetti POMA form is shown in the Appendix. The test will be performed at baseline
and 24 to 48 hours after correction of hyponatremia. The test will be conducted by the study
team.
The MOCA is a 30-point test administered in about 10 minutes designed to identify mild
cognitive impairment. The test is validated for a large variety of diseases ranging from
frontotemporal dementia to HIV or chronic obstructive pulmonary disease. The MOCA form is
shown in the Appendix. The test will be performed at baseline and 24 to 48 hours after
correction of hyponatremia. The test will be conducted by the study team.
Correction of hyponatremia Correction of hyponatremia will be performed at the discretion of
the attending physician depending on the etiology of hyponatremia. Hypovolemic hyponatremia
(diuretic induced hyponatremia, gastrointestinal fluid losses, low solute intake) will be
corrected by use of an isotonic crystalloid to replenish volume deficits and in a next step,
if needed, by use of loop diuretics to increase free water excretion and simultaneous
substitution of fluid losses by isotonic crystalloids until normonatremia (i.e. serum sodium
≥ 135 mmol/L) is reached. If hyponatremia is due to adrenal insufficiency steroids will be
applied in addition to volume resuscitation by use of isotonic crystalloids. In case of the
syndrome of inappropriate anti diuretic hormone secretion water restriction will be ordered
initially. Hyponatremia due to low effective circulating volume (heart failure, cirrhosis of
the liver) will be corrected by salt and water restriction. Serum sodium corrections will be
accompanied by frequent monitoring of serum sodium concentration. The study team will provide
the managing physician at the ward current expert recommendations on the correction of
hyponatremia in order to ensure best treatment for all study patients.
Sample size Sample size was calculated on basis of the MOCA test. To achieve a power of 90%
and a two-sided alpha level of 0.05, the sample size needed to detect a difference of 5
points (shown difference between normal individuals and those with mild cognitive impairment)
between the baseline and post-correction MOCA scores would be 44 patients. Thus, we plan to
enroll a total of 50 patients.
Statistical analysis Data will be presented as means and standard deviation or medians and
interquartile range as appropriate. Wilcoxon signed ranked tests will be used to compare
results on muscle strength, Tinetti score and MOCA scores, since those are not normally
distributed and samples will be dependent since every patient serves as his own control. A
p-value of ≤ 0.05 will be considered statistically significant. Statistics will be calculated
using SPSS Statistics, IBM Inc., Armonk, NY, USA.
Study period Based on general Patient count and prevalence of Hyponatremia, the enrollment of
the sample size of 50 patients seems realistic in a 12-month period, starting on 01 September
2019.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06037928 -
Plasma Sodium and Sodium Administration in the ICU
|
||
Recruiting |
NCT04561531 -
Efficacy and Safety of Bolus Comparing With Continuous Drip of 3% NaCl in Patients With Severe Symptomatic Hyponatremia.
|
N/A | |
Terminated |
NCT02012959 -
Study of the Safety and Effectiveness of SAMSCA® (Tolvaptan) in Children and Adolescents With Euvolemic or Hypervolemic Hyponatremia
|
Phase 3 | |
Recruiting |
NCT02936167 -
Comparison of Ringer Lactate and Isotonic Acetate Solution as Perioperative Maintenance Fluid for Children
|
N/A | |
Completed |
NCT00621348 -
Maintenance Intravenous Fluids in Children
|
Phase 3 | |
Terminated |
NCT03703713 -
Colloid Osmotic Pressure and Osmolality in Hyponatremia
|
||
Completed |
NCT02926989 -
Intravenous Fluids in Hospitalised Children
|
Phase 4 | |
Terminated |
NCT02959411 -
Tolvaptan for Advanced or Refractory Heart Failure
|
Phase 4 | |
Completed |
NCT02573077 -
An Observational Study Measuring Outcomes in Cancer Patients Treated for Moderate to Severe Hyponatremia in Italy
|
||
Withdrawn |
NCT02667977 -
Reexamining Hypotonic Intravenous Fluid Use
|
N/A | |
Terminated |
NCT01708811 -
Hyponatremia and Myometrium Contractility. An Invitro Study
|
N/A | |
Withdrawn |
NCT01326429 -
Frequency and Origin of Dysnatremias in the Emergency Department
|
N/A | |
Completed |
NCT01456533 -
Copeptin in the Differential Diagnosis of Dysnatremia in Hospitalized Patients
|
N/A | |
Terminated |
NCT01227512 -
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
|
Phase 3 | |
Recruiting |
NCT06013800 -
Hyponatremia Volume Status Analysis by Point-of-care Ultrasound
|
||
Withdrawn |
NCT02442674 -
A Trial of Tolvaptan in Children and Adolescent Subjects With Euvolemic and Hypervolemic Hyponatremia
|
Phase 3 | |
Completed |
NCT02545101 -
An Observational Study on Real-world Use and Outcomes of Patients Treated With Tolvaptan for Hyponatraemia Due to SIADH
|
N/A | |
Terminated |
NCT02215148 -
Pharmacokinetics and Clinical Response of Tolvaptan in Neurocritical Care Patients
|
N/A | |
Recruiting |
NCT01748331 -
The Effect of Fluid Restriction in Congestive Heart Failure Complicated With Hyponatremia
|
N/A | |
Not yet recruiting |
NCT01716611 -
Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites
|
Phase 4 |